Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (91-100 of 229) with videos related to

Pageof 23
Sort By:
Palliative Medicine|April 25, 2018
The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohortsMiriam J Johnson, Paula McSkimming, Alex McConnachie, et al.
Cost Effectiveness and Resource Allocation : C/E|May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspectiveDhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
Journal of Ophthalmology|March 27, 2010
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degenerationAdrian R Levy, Shelagh Szabo, Andrew Briggs, et al.
Developmental Child Welfare|March 30, 2026
Autism and attachment disorder symptoms in the general population: Prevalence, overlap, and burdenHelen Minnis, Claudia-Martina Messow, Alex McConnachie, et al.
Journal of Health Services Research & Policy|January 25, 2007
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical ExcellenceAnthony Culyer, Christopher McCabe, Andrew Briggs, et al.
Pharmacoeconomics|September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 PandemicYumi Asukai, Andrew Briggs, Louis P Garrison, et al.
Journal of the American College of Surgeons|September 5, 2020
Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA MelanomaYinin Hu, Andrew Briggs, Michael A Marchetti, et al.
Health Economics|December 21, 2005
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusionKarl Claxton, Mark Sculpher, Anthony Culyer, et al.
Journal of Comparative Effectiveness Research|January 24, 2022
Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillationAndrew Briggs, Amanda Howarth, Shawn Davies, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 1, 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisonsGabriel Tremblay, Tracy Westley, Joseph C Cappelleri, et al.
Pageof 23

Showing results (91-100 of 229) with videos related to

Sort By:
Pageof 23
Palliative Medicine|April 25, 2018
The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohortsMiriam J Johnson, Paula McSkimming, Alex McConnachie, et al.
Cost Effectiveness and Resource Allocation : C/E|May 19, 2018
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspectiveDhvani Shah, Maurice Driessen, Nancy Risebrough, et al.
Journal of Ophthalmology|March 27, 2010
Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degenerationAdrian R Levy, Shelagh Szabo, Andrew Briggs, et al.
Developmental Child Welfare|March 30, 2026
Autism and attachment disorder symptoms in the general population: Prevalence, overlap, and burdenHelen Minnis, Claudia-Martina Messow, Alex McConnachie, et al.
Journal of Health Services Research & Policy|January 25, 2007
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical ExcellenceAnthony Culyer, Christopher McCabe, Andrew Briggs, et al.
Pharmacoeconomics|September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 PandemicYumi Asukai, Andrew Briggs, Louis P Garrison, et al.
Journal of the American College of Surgeons|September 5, 2020
Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA MelanomaYinin Hu, Andrew Briggs, Michael A Marchetti, et al.
Health Economics|December 21, 2005
Discounting and cost-effectiveness in NICE - stepping back to sort out a confusionKarl Claxton, Mark Sculpher, Anthony Culyer, et al.
Journal of Comparative Effectiveness Research|January 24, 2022
Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillationAndrew Briggs, Amanda Howarth, Shawn Davies, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 1, 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisonsGabriel Tremblay, Tracy Westley, Joseph C Cappelleri, et al.
Pageof 23